miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells
Authors:
Open Access
- 5 July 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-16
Abstract
Tumor endothelial cells (TECs) reportedly exhibit altered phenotypes. We have demonstrated that TECs acquire drug resistance with the upregulation of P-glycoprotein (P-gp, ABCB1), contrary to traditional assumptions. Furthermore, P-gp expression was higher in TECs of highly metastatic tumors than in those of low metastatic tumors. However, the detailed mechanism of differential P-gp expression in TECs remains unclear. miRNA was identified in highly metastatic tumor extracellular vesicles (EVs) and the roles of miRNA in endothelial cell resistance were analyzed in vitro and in vivo. In the present study, we found that treatment of highly metastatic tumor-conditioned medium induced resistance to 5-fluorouracil (5-FU) with interleukin-6 (IL-6) upregulation in endothelial cells (ECs). Among the soluble factors secreted from highly metastatic tumors, we focused on EVs and determined that miR-1246 was contained at a higher level in highly metastatic tumor EVs than in low metastatic tumor EVs. Furthermore, miR-1246 was transported via the EVs into ECs and induced IL-6 expression. Upregulated IL-6 induced resistance to 5-FU with STAT3 and Akt activation in ECs in an autocrine manner. These results suggested that highly metastatic tumors induce drug resistance in ECs by transporting miR-1246 through EVs.Keywords
All Related Versions
Funding Information
- grants from Japan Agency for Medical Research and Development (JP18ck0106198h0003)
- Japan Society for the Promotion of Science (JP18K09715, JP18H02891, JP18H05092)
- Japan Agency for Medical Research and Development (JP19ck0106406h0002)
This publication has 58 references indexed in Scilit:
- STAT3 the oncogene – still eluding therapy?The FEBS Journal, 2015
- Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrierNature Communications, 2015
- Extracellular vesicles: biology and emerging therapeutic opportunitiesNature Reviews Drug Discovery, 2013
- Hypoxic enhancement of exosome release by breast cancer cellsBMC Cancer, 2012
- The Roles of Tumor-Derived Exosomes in Cancer PathogenesisJournal of Immunology Research, 2011
- Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancersMedicinal Research Reviews, 2010
- Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future DirectionsClinical Cancer Research, 2007
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell LymphomasNew England Journal of Medicine, 2004
- Altered angiogenesis and survival in human tumor‐derived endothelial cellsThe FASEB Journal, 2003